Project Grant R01AG100673
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $643K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute on Aging awarded The Washington University $651,035 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop predictive markers for amyloid-related imaging abnormalities in Alzheimer's disease patients treated with amyloid-targeted therapies. The project integrates data from two complementary cohorts: the Dominantly Inherited Alzheimer Network Trials Unit, the longest-treated anti-amyloid cohort with harmonized clinical, imaging, and biomarker data and...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded The Washington University $129,876 under the Aging Research program (CFDA 93.866) on June 15, 2026, to investigate the relationship between tau accumulation, white matter degeneration, and cognition in preclinical Alzheimer disease. The funded research uses autosomal dominant Alzheimer disease (ADAD) cohorts enrolled in the Dominantly Inherited Alzheimer Network (DIAN) to examine how tau tangle accumulation and white matter microstructural damage precede...
- The National Institute on Aging awarded The Washington University $150,114 on March 18, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of brain-engrafted monocyte-derived macrophages in Alzheimer's disease. The research examines how monocyte-derived macrophages infiltrating the brain contribute to Alzheimer's disease pathology. The F99 phase involves assessing the effects of promoting or depleting brain-engrafted monocyte-derived macrophages on amyloid plaque...
- The National Institute on Aging awarded The Washington University $246,225 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop an ultrasensitive, multiplexed plasmonic-fluor-linked immunosorbent assay (P-FLISA) for quantitative measurement of plasma phosphorylated tau 217 (P-TAU217), amyloid-beta 42 (AB42), and amyloid-beta 40 (AB40) as neurological biomarkers for early Alzheimer's disease detection. The project will deliver two specific research aims. Aim 1...
- The National Institute on Aging, an office of the National Institutes of Health, awarded the University of California, Davis $683,331 under the Aging Research program (CFDA 93.866) on September 1, 2026, to identify and validate causal risk genes and proteins contributing to Alzheimer's disease and its neuropsychiatric symptoms. The research integrates genome-wide association study (GWAS) findings with functional omics data from post-mortem brain tissues to pinpoint proteins mediating Alzheimer's...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Washington University $3,188,901 under the Aging Research program (CFDA 93.866) for a four-year project beginning September 1, 2025, and concluding August 31, 2029. This project grant supports research to map amyloid, tau, and neurodegeneration (ATN) biomarkers in relation to neuropsychiatric phenotypes and genotypes across the Alzheimer's disease continuum using machine learning methodologies. The research...
- The National Institute on Aging awarded a cooperative agreement valued at $6.273 million to The Washington University on March 1, 2026, under the Aging Research program (CFDA 93.866) to conduct the Caribbean Omics 'N' Genomics for Alzheimer Study (CONGAS). The award funds collection and analysis of genetic and multi-omic data from 5,000 elderly individuals (aged 65 and older) across Caribbean countries and Spain to address the underrepresentation of non-European ancestry populations in...
- The National Institute on Aging awarded The Leland Stanford Junior University $251,532 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic and proteomic pathways linking Alzheimer's disease to white matter hyperintensities in older adults. The research examines how Alzheimer's disease genetic liability drives white matter hyperintensity burden through circulating protein mediators, with particular focus on African American older adults who carry higher vascular...
- The National Institute on Aging awarded University of Massachusetts Medical School $445,130 on January 1, 2026, under the Aging Research program (CFDA 93.866) to support research elucidating the mechanisms by which MS4A genes regulate neurodegeneration in Alzheimer's disease and related disorders. The research investigates how genetic deletion and polymorphisms of MS4A family genes—particularly MS4A6C, MS4A4A, MS4A4E, and MS4A6E—affect disease progression across multiple neurodegenerative...